Impact of ferric carboxymaltose on the evolution of hemoglobin and ECOG performance status in iron-deficient patients with solid tumors: a 3-month follow-up retrospective study

Supportive Care in Cancer

Volumn 26, Issue 11, 2018, Pages 3827-3834

  Coussirou, J ^a   Debourdeau, A ^b   Stancu, A ^a   Jean, C ^a   Azouza, W ^a   Chanet, B ^a   De Crozals, F ^a   Boustany, R ^a   Debourdeau, P ^a  

^a INSTITUT SAINTE CATHERINE   (France)

^b HÔPITAL SAINT ELOI   (France)

Author keywords

Cancer patients; Ferric carboxymaltose; Iron deficiency; Iron therapy; Performance status

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; FERRIC ION; MALTOSE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; ECOG INDEX; FEMALE; FOLLOW UP; FUNCTIONAL STATUS ASSESSMENT; HUMAN; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOLID MALIGNANT NEOPLASM; UNIVARIATE ANALYSIS; ANALOGS AND DERIVATIVES; BLOOD; BLOOD TRANSFUSION; COMPLICATION; HEALTH STATUS INDICATOR; IRON DEFICIENCY ANEMIA; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY; QUALITY OF LIFE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; BLOOD TRANSFUSION; FEMALE; FERRIC COMPOUNDS; FERRITINS; FOLLOW-UP STUDIES; HEALTH STATUS INDICATORS; HEMOGLOBINS; HUMANS; MALE; MALTOSE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85047369209     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-018-4250-x     Document Type: Article

References (26)

1. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293–2306
2. Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y (2012) Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 23:1954–1962
3. Neoh K, Stanworth S, Pasricha SR, Bennett MI (2017 Apr) Estimating prevalence of functional iron deficiency anaemia in advanced cancer. Support Care Cancer 25(4):1209–1214
4. Kanuri G, Sawhney R, Varghese J, Britto M, Shet A (2016) Iron deficiency anaemia coexists with cancer related anaemia and adversely impacts quality of life. PLoS One 11(9):e0163817
5. Adamson JW (2008) The anemia of inflammation/malignancy: mechanisms and management. Hematology Am Soc Hematol Educ Program:159–165
6. Ludwig H, Aapro M, Bokemeyer C, Glaspy J, Hedenus M, Littlewood TJ, Österborg A, Rzychon B, Mitchell D, Beguin Y (2014) A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer 22(8):2197–2206
7. Ludwig H, Müldür E, Endler G, Hübl W (2013) Prevalence of iron deficiency across different tumours and its association with poor performance status, disease status and anemia. Ann Oncol 24(7):1886–1892
8. Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, Gasche C (2014) Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women-PREFER a randomized, placebo-controlled study. PLoS One 9:e94217
9. Rayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G (2011) Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 118:3222–3227
10. NCCN Clinical Practice Guidelines in Oncology. Cancer and chemotherapy induced anemia, version 2-2017. https://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf
11. Munoz M, Martin-Montanez E (2012) Ferric carboxymaltose for the treatment of iron-deficiency anemia. Expert Opin Pharmacother 13:907–921
12. Toledano A, Luporsi E, Morere JF, Scotté F, Laribi K, Barrière J, Huot-Marchand P, Duvillié L, Concas VH, Bugat R (2016) Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Support Care Cancer 24:67–75
13. Preston NJ, Hurlow A, Brine J, Bennett MI (2012 Feb 15) Blood transfusions for anaemia in patients with advanced cancer. Cochrane Database Syst Rev 2:CD009007. 10.1002/14651858.CD009007
14. Gafter-Gvili A, Rozen-Zvi B, Vidal L, Leibovici L, Vansteenkiste J, Gafter U, Shpilberg O (2013) Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia—systematic review and meta-analysis of randomised controlled trials. Acta Oncol 52:18–29
15. Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B (2016 Feb 4) The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev 2:CD009624
16. Borstlap WA, Stellingwerf ME, Moolla Z, Musters GD, Buskens CJ, Tanis PJ, Bemelman WA (2015) Iron therapy for the treatment of preoperative anaemia in patients with colorectal carcinoma: a systematic review. Color Dis 17:1044–1054
17. Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, Kim JH, Kim JW (2007) Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 105:199–204
18. Calleja JL, Delgado S, del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F, Colon Cancer Study Group (2016) Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int J Color Dis 31:543–551
19. Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N (2013) Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 24:475–482
20. Lebrun F, Klastersky J, Levacq D, Wissam Y, Paesmans M (2017) Intravenous iron therapy for anemic cancer patients: a review of recently published clinical studies. Support Care Cancer 25:2313–2319
21. Lind M, Vernon C, Cruickshank D, Wilkinson P, Littlewood T, Stuart N, Jenkinson C, Grey-Amante P, Doll H, Wild D (2002) The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 22(86):1243–1249
22. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA (2002) Relationship between changes in Hb level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888–895
23. Kanuri G, Sawhney R, Varghese J, Britto M, Shet A (2016) Iron deficiency anaemia coexists with cancer related anaemia and adversely impacts quality of life. PLoS One 11:e0163817
24. Dangsuwan P, Manchana T (2010) Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 116:522–525
25. Blagden SP, Charman SC, Sharples LD, Magee LRA, Gilligan D (2003) Performance status score: do patients and their oncologists agree? Br J Cancer 89:1022–1027
26. Kelly CM, Shahrokni A (2016) Moving beyond Karnofsky and ECOG performance status assessments with new technologies. J Oncol 2016:6186543